Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494541 · ClinicalTrials.gov registry record
Characteristics of Patients With Sickle Cell Disease
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 540
- Enrollment target
NCT05494541: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05494541 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05494541 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
Primary Outcome
Age information was reported.
Interventions
- OTHER Crizanlizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2021-10-27 |
What the finished NCT05494541 record still lists
NCT05494541 is an observational study that tracks outcomes without assigning an intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Crizanlizumab is the first listed.
NCT05494541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05494541 about?
NCT05494541 is a clinical study titled "Characteristics of Patients With Sickle Cell Disease". This was a retrospective descriptive analysis of health care claims data using the IQVIA open source medical and pharmacy claims databases.
What is the current status of trial NCT05494541?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2021-08-30. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT05494541?
The interventions under investigation include: Crizanlizumab (OTHER).
Who is sponsoring clinical trial NCT05494541?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI